ARCHIVES

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: Ginder To direct Massey Cancer Center; UAB Receives $1 Million for Genetics Chair

August 15, 1997

Tivozanib Does Not Improve OS Compared to Sorafenib

February 22, 2013

Mytomycin C, RT Improve Head & Neck Results, Sartorelli Reports; Other AACR, ASCO Lectures

June 5, 1987

FDA Grants Priority Review To Two Drugs in NSCLC

February 22, 2013

Conferees Set $1.991 Bil. NCI Budget, Ax Earmark For Breast Cancer, But Find $210 Mil. In Defense

October 9, 1992

Cranial Radiation Eliminated With Personalized Chemo

August 28, 2009